Tag: Top Story

Kymriah and the CAR-T roller coaster

Last week, Novartis’ CAR-T immunotherapy, Kymriah (tisagenlecleucel), was approved for children and young adults with relapsed B-cell acute lymphoblastic leukemia (ALL). The excitement was palpable as this first gene...

Read More
Loading

Our Facebook Page

Facebook By Weblizar Powered By Weblizar